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Invasive aspergillosis (IA) is a leading cause of infectious mortality in patients who have 
undergone a hematopoietic stem cell transplant (HSCT); the mortality due to IA ranges 
from 70% to 93% in HSCT patients. Early diagnosis and treatment are the cornerstones 
for the good prognosis of IA. Primary renal aspergillosis is an extremely rare presentation 
in patients who have undergone HSCT, and the risk factor for this uncommon presentation 
is not well known. We report a patient who developed primary renal aspergillosis and 
renal stones in both the kidneys after HSCT. Invasive renal aspergillosis was diagnosed 
after a nephrectomy, which was performed to treat massive renal hematoma.
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INTRODUCTION
  Invasive aspergillosis (IA) is a major cause of morbidity 
and mortality in patients who have undergone a hema-
topoietic stem cell transplant (HSCT). The common sites 
of IA include lung, central nervous system, and paranasal 
sinuses. Primary renal aspergillosis is extremely rare; it has 
been mostly reported in immunocompromised patients. In 
Korea, only 3 cases of primary renal aspergillosis have been 
reported [1-3], but none were associated with HSCT. We 
report a patient who developed primary renal aspergillosis 
and renal stones in both the kidneys after HSCT. Invasive 
renal aspergillosis was diagnosed after nephrectomy, which 
was performed to treat massive renal hematoma.
CASE REPORT
  A 33-year-old man was hospitalized after experiencing 
general weakness for 1 month. His medical history was 
unremarkable. Bone marrow examination revealed acute 
myeloid leukemia (AML). He received induction chemo-
therapy comprising continuous infusion of cytarabine (100 
mg/m
2) for 7 days and bolus injection of idarubicin (12 mg/m
2) 
for 3 days. He achieved complete remission, and the same 
drugs were administered during consolidation chemo-
therapy. At the end of the first consolidation chemotherapy, 
he visited the outpatient clinic because of severe headache. 
Cerebrospinal fluid (CSF) cytology confirmed leukemia re-
lapse in the central nervous system (CNS). Bone marrow 
examination did not show any evidence of hematologic 
relapse. Isolated CNS relapse was treated by intrathecal in-
jection of methotrexate (12 mg; twice weekly). After the 
4th injection, leukemic blasts in the CSF were unidentifiable. 
Therefore, methotrexate injection was discontinued after 2 
additional courses. The patient received allogeneic peripheral 
blood SCT from a HLA-2-mismatched unrelated donor. 
Abdominal ultrasonography before the transplant had re-
vealed renal stones with hydronephrosis in the right kidney. 
Since the patient had no specific symptoms related to renal 
stones, HSCT was continued without further treatment for 
renal stones. The conditioning regimen comprised busulphan 
(3.2 mg/kg; IV; 4 days) and cyclophosphamide (60 mg/kg; 
IV; 2 days). Tacrolimus and short-course methotrexate were 
administered for the prophylaxis of graft-versus-host disease Korean J Hematol 2010;45:275-8.
276 Hyunsung Park, et al. 
Fig. 1. Multiple renal and ureteral stones (arrow) with hydronephrosis.
Fig. 2. Images of the renal parenchymal tearing with active bleeding, subcapsular hematoma in the right kidney (left panel), and prostate abscess
(right panel).
(GVHD). Micafungin (50 mg daily; IV) was administered 
for anti-fungal prophylaxis from the 1st day of conditioning 
chemotherapy until engraftment. After engraftment, itraco-
nazole (200 mg) solution was orally administered daily.
  On the 19th day of transplantation, complete engraftment 
was achieved, and the absolute neutrophil count was 
1,015/μL. The patient was discharged on day 27. Nonoliguric 
acute renal failure developed during the transplant period. 
The estimated glomerular filtration rate (as per Modification 
of diet in renal disease equation) was steady between 40 
and 70 mL/min/m
2; this was considered as a side effect of 
the calcineurin inhibitor. There were no symptoms and signs 
of acute GVHD. The serum was negative for Aspergillus 
galactomannan antigen, and itraconazole oral solution was 
substituted by fluconazole (100 mg; twice daily) peroral (PO) 
at the outpatient clinic.
  On day 74, he presented with right flank pain. Abdominal 
ultrasonography and non-contrast-enhanced abdominal 
computed tomography (CT) revealed multiple renal and ure-
teral stones with right hydronephrosis (Fig. 1) but no radio-
logic evidence of fungal infection in the kidney.
  After urologic consultation, the patient was scheduled for 
extracorporeal shock wave lithotripsy (ESWL) for stone re-
moval, but a febrile episode occurred. No pathogen was iden-
tified in the blood, sputum, and urine culture. PCR showed 
positive findings for cytomegalovirus (CMV) before the fe-
brile episode, but the result of the consecutive test was neg-
ative without any anti-CMV treatment. 
  On day 75, serum analysis yielded positive findings for 
Aspergillus galactomannan antigen, and the consecutive test 
after 2 d also yielded positive findings (titer, 3.03). Non-con-
trast-enhanced chest CT and ostiomeatal unit CT showed 
no evidence of airway, pulmonary, or paranasal aspergillosis. 
Cefepime (2 g, IV) was administered twice daily for empirical 
broad-spectrum antibacterial therapy and amphotericin B 
deoxycholate (1 mg/kg/day) for empirical antifungal therapy. 
Subsequently, the fever subsided, and the patient underwent 
2 courses of ESWL. The cumulative dose of amphotericin 
B deoxycholate reached 800 mg, and after discharge, the 
patient received itraconazole (400 mg) oral solution because 
the serum was still positive for Aspergillus galactomannan 
antigen.
  On day 96, the patient was admitted because of headache 
and right flank pain. Magnetic resonance imaging (MRI) 
of the brain revealed leptomeningeal leukemic infiltration, 
and CSF cytology confirmed the presence of CNS leukemia. 
Abdominal CT revealed residual multiple renal and ureteral 
stones in both kidneys. The serum Aspergillus galactomannan 
antigen titer was still high (3.32). For treatment of isolated 
CNS relapse, intrathecal methotrexate injection was ad-
ministered twice. Ureteroscopic lithotripsy and ureteral stent 
placement were performed for stones in the right kidney 
and ureter. The right flank pain subsided immediately after 
ureteroscopy. However, 4 days later, the pain aggravated 
and fever developed. Abdominal CT showed a large sub-
capsular hematoma in the right kidney and abscess-like lesion 
in the prostate gland (Fig. 2). The WBC and platelet counts 
decreased to 150/μL and 33,000/μL, respectively.
  On day 109, emergency radical nephrectomy was performed Korean J Hematol 2010;45:275-8.
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Fig. 4. Renal biopsy showing renal parenchymal and vascular invasion by Aspergillus hyphae (left panel, Periodic Acid Schiff (PAS) stain, ×100; right
panel, PAS stain, ×200).
Fig. 3. Right kidney with perirenal hematoma after radical nephrec-
tomy.
(Fig. 3), and a ruptured area in the mid-portion of the lateral 
side of the right kidney was observed. Moreover, multiple 
fungal hyphae with septae and branching at acute angles 
in the renal parenchyma with vascular invasion, which was 
morphologically consistent with renal aspergillosis, were ob-
served (Fig. 4). The identity of the causative fungal pathogen 
was inconclusive. The abscess-like lesion in the prostate was 
not manipulated because of the risk for hemorrhage. The 
patient was initially treated with meropenem and vancomy-
cin for broad-spectrum antibacterial coverage and amphoter-
icin B deoxycholate for empirical antifungal coverage after 
the development of fever. After confirmation of renal asper-
gillosis, voriconazole was administered instead of amphoter-
icin B deoxycholate at the intensive care-unit after the oper-
ation, but the patient died on day 113 because of sepsis 
progression.
DISCUSSION
  Aspergillus  is a filamentous fungus occurring naturally 
worldwide. Aspergillus spp., Fusarium spp., and Pseudalle-
scheria boydii show branched septate hyphae with angioin-
vasion, but Fusarium spp. show branching at right angles 
and constriction at their site of origin from parent hyphae 
and Pseudallescheria boydii show haphazard branching with 
prominent vesicles [4]. More than 900 species of Aspergillus 
exist, but less than 20 are pathogenic to humans [3]. 
Aspergillus fumigatus is the most common causative patho-
gen in invasive aspergillosis, followed by A. flavus, A. niger, 
and  A. terreus [3].
  IA is a leading cause of infectious mortality after HSCT. 
Although supportive care has improved and new antifungal 
agents and sensitive tests such as Aspergillus galactomannan 
antigen assay have been developed, mortality due to IA is 
high (70-93%) in HSCT patients [5]. The incidence of IA 
among the HSCT recipients has increased since the 1990s; 
this may be attributed to the grafts obtained from high-risk 
donors, increased profound immunosuppression, and pro-
phylaxis with fluconazole, which is active against most 
Candida species but not against Aspergillus species. In recent 
years, IA has been the most common invasive fungal infection 
(IFI) following HSCT, accounting for 59% of IFIs [6].
  In 2008, the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative 
Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group (EORTC/MSG) classified IFI 
into proven, probable, or possible disease [7]. The Aspergillus 
galactomannan antigen test forms a part of the reference 
standard for diagnosing IA under the EORTC/MSG criteria. Korean J Hematol 2010;45:275-8.
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The sensitivity and specificity o f  t h is  t e s t  w e r e  7 1 %  a n d  
89%, respectively, for proven cases, and 61% and 93% for 
proven and probable cases, respectively, in patients with 
neutropenia or other hematologic conditions [8], although 
false positive results may be obtained from patients receiving 
piperacillin, amoxicillin, or ticarcillin [9].
  In our patient, the positive finding of serum galactomannan 
was first reported on day 75, and the subsequent tests were 
positive, with a continuously high titer. According to the 
EORTC/MSG classification, we diagnosed the patient with 
possible fungal infection and treated him with amphotericin 
B deoxycholate. Unfortunately, after 2 weeks of treatment, 
the serum galactomannan levels did not decrease, which 
may be attributed to the following reasons. First, although 
amphotericin B is used as a standard therapy for IA, only 
13.3% of patients who had undergone allogenic HSCT had 
shown a favorable response [10]. Second, since amphotericin 
B is excreted mainly via the biliary tract (42%) and only 
a low percentage is excreted via the kidney (24%) [3], there 
is a possibility that the amphotericin B deoxycholate concen-
tration is not sufficient to eliminate Aspergillus from the 
kidney. Finally, although Aspergillus species are rarely re-
sistant to amphotericin B, the patient may have been infected 
by A. terreus, which is intrinsically resistant to amphotericin 
B. Itraconazole, which was administered subsequently after 
amphotericin B deoxycholate, is active against most Asper-
gillus species, including A. terreus. However, since itracona-
zole is mostly excreted in the feces, it may not be effective 
against renal aspergillosis. Therefore, surgical treatment of 
renal aspergillosis may achieve a good outcome [3]. If surgery 
cannot be performed, voriconazole and/or caspofungin can 
be administered, though the data on their efficacies are still 
limited [10, 11]. In our case, the patient had undergone 
radical nephrectomy, during which renal aspergillosis was 
incidentally observed. Extensive imaging studies were per-
formed before surgery, but contrast non-enhanced CT scan 
and ultrasonography were not sufficient to identify the fungal 
lesions in the kidney. If IA is highly suspected in patients 
with kidney complications, aggressive diagnostic approaches, 
including contrast-enhanced imaging study (e.g., CT and 
MRI) may facilitate an accurate diagnosis and improve the 
treatment outcome.
  In the only report of primary renal aspergillosis following 
HSCT, the patient had a stone in the renal pelvis [12]; this 
clinical presentation was similar to that observed in our 
patient. Many other reports have described the simultaneous 
presentation of renal aspergillosis and urinary tract stones. 
Haq et al. [13] reported primary renal aspergillosis in a dia-
betic patient with renal stones and Godec et al. and Eisenberg 
et al. reported cases with primary renal aspergillosis and 
obstruction at the ureteropelvic junction [14, 15]. These find-
ings may suggest that urinary stasis induced by urinary tract 
obstruction may play some role in the development of renal 
aspergillosis.
  In conclusion, the development of primary renal aspergil-
losis following HSCT is extremely rare, but if fungal infection 
is suspected in a patient with a urinary tract obstruction, 
especially with renal stones, renal aspergillosis must be con-
sidered in the differential diagnosis.
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